Related Experiment Video
Updated: Jul 20, 2025
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Notopterol alleviates the progression of osteoarthritis: An in vitro and in vivo study
1Key Laboratory of Drug-Targeting and Drug Delivery System of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu 610106, China; School of Food and Biological engineering, Chengdu University, Chengdu 610106, China.
Abstract:
Osteoarthritis (OA) is a prevalent degenerative joint disorder caused by the progressive destruction of cartilage and inflammation in the articular cavity. Studies have proved that the inhibition of articular cartilage destruction and generation of inflammatory factors can be effective strategies for treating OA. Notopterol (NOT) is a quality control index of Notopterygium incisum Ting ex H. T. Chang (N. incisum) with anti-inflammatory, antioxidant, and analgesic activities. Moreover, NOT has been used for many years to treat joint diseases. A study using human C28/I2 cells suggested that NOT down-regulated the hypersecretion of inflammatory mediators and alleviated the degradation of the extracellular matrix (ECM). In addition, NOT decreased the overproduction of reactive oxygen species (ROS) and chondrocyte apoptosis through the nuclear factor erythroid-2-related factor 2 (Nrf2) signaling pathway. NOT exerted a chondroprotective effect by partly inhibiting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathways and regulating the nuclear factor Nrf2/heme oxygenase-1(HO-1) signaling pathway. In vivo, NOT improved the destruction of articular cartilage in a rat OA model, which may be related to the inhibition of tumor necrosis factor α (TNF-α), interleukin (IL)-1β, IL-6, and IL-12 expressions in synovial fluid. In summary, these results showed that NOT alleviated the progression of OA and is expected to become a new therapy for treating OA clinically.
Insights
Notopterol (NOT) effectively treats osteoarthritis (OA) by reducing cartilage destruction and inflammation. This natural compound shows promise as a new clinical therapy for joint disease.
Area of Science:
- Pharmacology
- Biochemistry
- Orthopedics
Background:
- Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage destruction and inflammation.
- Current OA treatments focus on inhibiting cartilage breakdown and inflammatory factor generation.
Purpose of the Study:
- To investigate the therapeutic potential of Notopterol (NOT), a compound from N. incisum, for osteoarthritis.
- To elucidate the molecular mechanisms underlying NOT's chondroprotective effects.
Main Methods:
- In vitro study using human C28/I2 chondrocytes to assess NOT's effects on inflammatory mediators, extracellular matrix (ECM) degradation, reactive oxygen species (ROS), and apoptosis.
- Investigation of NOT's impact on key signaling pathways: Nrf2/HO-1, JAK2/STAT3, and PI3K/AKT.
- In vivo study using a rat OA model to evaluate NOT's efficacy in improving articular cartilage destruction and reducing inflammatory cytokine levels.
Main Results:
- NOT down-regulated inflammatory mediators and alleviated ECM degradation in chondrocytes.
- NOT reduced ROS production and chondrocyte apoptosis via the Nrf2 signaling pathway.
- NOT demonstrated chondroprotective effects by modulating JAK2/STAT3, PI3K/AKT, and Nrf2/HO-1 pathways.
- In vivo, NOT improved articular cartilage in a rat OA model, likely by inhibiting TNF-α, IL-1β, IL-6, and IL-12.
Conclusions:
- Notopterol (NOT) effectively alleviates osteoarthritis progression.
- NOT exhibits chondroprotective properties through multiple molecular pathways.
- NOT is a promising candidate for novel clinical therapies for osteoarthritis.
